147 related articles for article (PubMed ID: 38572526)
1. Decreased risk of renal cell carcinoma in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors.
Chiu CH; Wang WY; Chen HY; Liao PL; Jong GP; Yang TY
Cancer Sci; 2024 Jun; 115(6):2059-2066. PubMed ID: 38572526
[TBL] [Abstract][Full Text] [Related]
2. Type Disparity in Sodium-Glucose Cotransporter-2 Inhibitors in Incidences of Renal Cell Carcinoma: A Propensity-Score-Matched Cohort Study.
Lin TK; Wang WY; Yang TY; Jong GP
Cancers (Basel); 2024 Jun; 16(11):. PubMed ID: 38893264
[TBL] [Abstract][Full Text] [Related]
3. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
Au PCM; Tan KCB; Lam DCL; Cheung BMY; Wong ICK; Kwok WC; Sing CW; Cheung CL
JAMA Netw Open; 2023 Jan; 6(1):e2251177. PubMed ID: 36648944
[TBL] [Abstract][Full Text] [Related]
4. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease.
Yen FS; Hwu CM; Liu JS; Wu YL; Chong K; Hsu CC
Ann Intern Med; 2024 Jun; 177(6):693-700. PubMed ID: 38684099
[TBL] [Abstract][Full Text] [Related]
5. Psychiatric disorders in patients with type 2 diabetes mellitus on sodium-glucose cotransporter-2 inhibitors-a nationwide retrospective cohort study.
Hu WS; Lin CL
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; 397(1):575-581. PubMed ID: 37490120
[TBL] [Abstract][Full Text] [Related]
6. Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study.
Jeong HE; Park S; Noh Y; Bea S; Filion KB; Yu OHY; Jang SH; Cho YM; Yon DK; Shin JY
BMC Med; 2023 Feb; 21(1):47. PubMed ID: 36765407
[TBL] [Abstract][Full Text] [Related]
7. Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes.
Paik JM; Tesfaye H; Curhan GC; Zakoul H; Wexler DJ; Patorno E
JAMA Intern Med; 2024 Mar; 184(3):265-274. PubMed ID: 38285598
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
Lee S; Zhou J; Leung KSK; Wai AKC; Jeevaratnam K; King E; Liu T; Wong WT; Chang C; Wong ICK; Cheung BMY; Tse G; Zhang Q
Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921
[TBL] [Abstract][Full Text] [Related]
10. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes.
Yen FS; Wei JC; Yu TS; Hung YT; Hsu CC; Hwu CM
JAMA Netw Open; 2023 Dec; 6(12):e2348431. PubMed ID: 38117497
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs Glucagonlike Peptide-1 Receptor Agonists and Incidence of Dry Eye Disease in Patients With Type 2 Diabetes in Taiwan.
Su YC; Hung JH; Chang KC; Sun CC; Huang YH; Lee CN; Hung MJ; Lai CC; Shao SC; Lai EC
JAMA Netw Open; 2022 Sep; 5(9):e2232584. PubMed ID: 36136333
[TBL] [Abstract][Full Text] [Related]
12. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.
Dave CV; Kim SC; Goldfine AB; Glynn RJ; Tong A; Patorno E
Circulation; 2021 Feb; 143(8):770-779. PubMed ID: 33302723
[TBL] [Abstract][Full Text] [Related]
13. Risk of New-onset Stroke in Patients with Type 2 Diabetes with Chronic Kidney Disease on Sodium-glucose Co-transporter-2 Inhibitor Users.
Jong GP; Lin TK; Liao PL; Huang JY; Yang TY; Pan LF
Transl Stroke Res; 2023 Jul; ():. PubMed ID: 37442919
[TBL] [Abstract][Full Text] [Related]
14. Association of sodium-glucose cotransporter 2 inhibitors with risk of major adverse cardiovascular events in type 2 diabetes patients with acute coronary syndrome: a propensity score‑matched analysis.
Liu T; Fan Z; Xiao B; He C; Wang S
Cardiovasc Diabetol; 2024 Mar; 23(1):106. PubMed ID: 38528542
[TBL] [Abstract][Full Text] [Related]
15. New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study.
Gao X; Zhang N; Lu L; Gao T; Chou OHI; Wong WT; Chang C; Wai AKC; Lip GYH; Zhang Q; Tse G; Liu T; Zhou J
Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):103-117. PubMed ID: 37962962
[TBL] [Abstract][Full Text] [Related]
16. Renal outcomes with sodium-glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases.
Iijima H; Gouda M; Hida H; Mori-Anai K; Takahashi A; Minai R; Ninomiya H; Saito Y; Miyawaki A; Wada J
Diabetes Obes Metab; 2024 May; 26(5):1615-1623. PubMed ID: 38413384
[TBL] [Abstract][Full Text] [Related]
17. Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.
Schechter M; Melzer-Cohen C; Rozenberg A; Yanuv I; Chodick G; Karasik A; Kosiborod M; Mosenzon O
Cardiovasc Diabetol; 2021 Aug; 20(1):169. PubMed ID: 34407822
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
Jang J; Park S; Kim S; Kim SH; Oh YS; Sa YK; Hwang Y; Jang SW; Ihm SH; Choi Y
Eur J Prev Cardiol; 2024 Feb; 31(3):320-329. PubMed ID: 37798123
[TBL] [Abstract][Full Text] [Related]
19. Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and the Incidence of Acute Kidney Injury in Taiwan.
Chung MC; Hung PH; Hsiao PJ; Wu LY; Chang CH; Hsiao KY; Wu MJ; Shieh JJ; Huang YC; Chung CJ
JAMA Netw Open; 2023 Feb; 6(2):e230453. PubMed ID: 36811856
[TBL] [Abstract][Full Text] [Related]
20. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.
Zhou J; Lee S; Leung KSK; Wai AKC; Liu T; Liu Y; Chang D; Wong WT; Wong ICK; Cheung BMY; Zhang Q; Tse G
ESC Heart Fail; 2022 Apr; 9(2):1388-1399. PubMed ID: 35132823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]